Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127449471 | 12744947 | 1 | I | 20160729 | 20160915 | 20160915 | PER | RS-NOVEL LABORATORIES, INC-2016-03497 | NOVEL LABS | COLOVIC N, SEFEROVIC P, PLECIC M, VIDOVIC A, SUVAJDZIC N, TOMIN D. PERIPARTUM CARDIOMYOPATHY IN A PATIENT TREATED FOR ACUTE MYELOID LEUKEMIA. SERBIAN ARCHIVES OF MEDICINE. 2016;144(1-2):77-80. | 30.00 | YR | F | Y | 0.00000 | 20160914 | COUNTRY NOT SPECIFIED | RS |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127449471 | 12744947 | 1 | SS | FLUCONAZOLE. | FLUCONAZOLE | 1 | Unknown | UNKNOWN | 0 | ||||||||||
| 127449471 | 12744947 | 2 | PS | VORICONAZOLE. | VORICONAZOLE | 1 | Unknown | UNKNOWN | 207371 | ||||||||||
| 127449471 | 12744947 | 3 | SS | AMPHOTERICIN B. | AMPHOTERICIN B | 1 | Unknown | UNKNOWN | 0 | ||||||||||
| 127449471 | 12744947 | 4 | SS | ITRACONAZOLE. | ITRACONAZOLE | 1 | Unknown | UNKNOWN | 0 | ||||||||||
| 127449471 | 12744947 | 5 | SS | Doxorubicin | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | DAY 1, 3, 5 | UNKNOWN | 0 | |||||||||
| 127449471 | 12744947 | 6 | SS | MITOXANTRONE | MITOXANTRONE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | DAY 1 TO DAY 4 | UNKNOWN | 0 | |||||||||
| 127449471 | 12744947 | 7 | C | CYTARABINE. | CYTARABINE | 1 | Intravenous bolus | DAY 1 TO DAY 8 | UNKNOWN | 0 | 140 | MG | BID | ||||||
| 127449471 | 12744947 | 8 | C | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | DAY 1 TO DAY 3 | UNKNOWN | 0 | 3 | G | BID | ||||||
| 127449471 | 12744947 | 9 | C | CYTARABINE. | CYTARABINE | 1 | Intravenous drip | DAY 1 TO DAY 5 | UNKNOWN | 0 | 150 | MG | BID | ||||||
| 127449471 | 12744947 | 10 | C | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous bolus | DAY 1 TO DAY 5 | UNKNOWN | 0 | 140 | MG | BID | ||||||
| 127449471 | 12744947 | 11 | C | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | DAY 1 TO DAY 5 | UNKNOWN | 0 | 150 | MG | BID | ||||||
| 127449471 | 12744947 | 12 | C | Amsacrine | AMSACRINE | 1 | Intravenous bolus | DAY 1 TO DAY 5 | UNKNOWN | 0 | 15 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127449471 | 12744947 | 1 | Hepatosplenic candidiasis |
| 127449471 | 12744947 | 2 | Hepatosplenic candidiasis |
| 127449471 | 12744947 | 3 | Hepatosplenic candidiasis |
| 127449471 | 12744947 | 4 | Hepatosplenic candidiasis |
| 127449471 | 12744947 | 5 | Acute myeloid leukaemia |
| 127449471 | 12744947 | 6 | Acute myeloid leukaemia |
| 127449471 | 12744947 | 7 | Acute myeloid leukaemia |
| 127449471 | 12744947 | 10 | Acute myeloid leukaemia |
| 127449471 | 12744947 | 12 | Acute myeloid leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127449471 | 12744947 | LT |
| 127449471 | 12744947 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127449471 | 12744947 | Peripartum cardiomyopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127449471 | 12744947 | 8 | 200411 | 0 | ||
| 127449471 | 12744947 | 9 | 200409 | 0 | ||
| 127449471 | 12744947 | 11 | 200409 | 0 |